Facebook Twitter Linkedin

News

Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004

Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004

Milestone marks transition of Inimmune Corporation to a clinical-stage company MISSOULA, Mont., Aug. 2, 2023 /PRNewswire/ — Inimmune Corporation (“Inimmune”),…
Read More
Development of Novel STING Agonists as Vaccine Adjuvants

Development of Novel STING Agonists as Vaccine Adjuvants

Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies, and delivery systems, announced today that…
Read More
Inimmune attends BIO International Convention and provides an update on company programs and transition to a clinical stage biotech company.

Inimmune attends BIO International Convention and provides an update on company programs and transition to a clinical stage biotech company.

Missoula, MT, June 5, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies…
Read More
Inimmune to Play a Key Role at the World Vaccine Congress on April 3-6, 2023

Inimmune to Play a Key Role at the World Vaccine Congress on April 3-6, 2023

MISSOULA, Mont., March 29, 2023 /PRNewswire/ — Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants,…
Read More
Inimmune Co-Founder and Chief Scientific and Strategy Officer, Dr. Jay Evans, will be a featured panelist at the 2023 MT Economic Outlook Seminar

Inimmune Co-Founder and Chief Scientific and Strategy Officer, Dr. Jay Evans, will be a featured panelist at the 2023 MT Economic Outlook Seminar

Inimmune Co-Founder and Chief Scientific and Strategy Officer, Dr. Jay Evans, will be a featured panelist at the 2023 MT…
Read More
Bioscience research and development can unlock the economic potential of the Mountain West

Bioscience research and development can unlock the economic potential of the Mountain West

Bioscience research and development can unlock the economic potential of the Mountain West, providing jobs and substantial economic benefit.  Read…
Read More
Science Behind the Silent Killer

Science Behind the Silent Killer

To passing eyes, the town of Puyallup where Tomi Cook spent her high school years looks the perfect picture of…
Read More
Development of COVID-19 Vaccine, Tests Advancing in Montana

Development of COVID-19 Vaccine, Tests Advancing in Montana

Inimmune Corporation is joining in on efforts to develop a COVID-19 vaccine with a nasal spray that could offer protection…
Read More
Montana Biotech Company Receives $2 M Small Business Innovation Research Grant to Advance Vaccine Technologies

Montana Biotech Company Receives $2 M Small Business Innovation Research Grant to Advance Vaccine Technologies

Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded a $2 M grant from the National Institute…
Read More
Biotech Company Announces $22 Million Investment Led by Mike Goguen’s Firm

Biotech Company Announces $22 Million Investment Led by Mike Goguen’s Firm

Inimmune, a Missoula-based biotech company founded by nationally recognized vaccine scientists that has been working on a vaccine for COVID-19,…
Read More
Inimmune raises $22 Million in Series A Funding Led by Two Bear Capital

Inimmune raises $22 Million in Series A Funding Led by Two Bear Capital

(Missoula, MT) Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised…
Read More
UM Receives Largest Single Research Award in its History

UM Receives Largest Single Research Award in its History

MISSOULA – The National Institutes of Health has awarded the University of Montana a five-year, $33.4 million award for the development…
Read More
Nation angler Evans helping with vital COVID research

Nation angler Evans helping with vital COVID research

LAKE HAVASU CITY, Ariz. — Many anglers like to escape to the water, leaving the cares of the world back…
Read More
For Missoula’s Inimmune, a $22 M Series A Round with Two Bear Capital is the latest record set – MT High Tech Business Alliance

For Missoula’s Inimmune, a $22 M Series A Round with Two Bear Capital is the latest record set – MT High Tech Business Alliance

In July 2020, Missoula-based biotech therapeutics company Inimmune Corporation announced the largest Series A investment in Montana history: a $22…
Read More
The Rise of Venture Capital in Montana

The Rise of Venture Capital in Montana

When the Bozeman-based venture capital firm Next Frontier Capital was founded in 2015, Montana ranked dead last in the United…
Read More
Inimmune receives Small Business Innovation Research Contract to develop novel treatments targeting Allergic Rhinitis.

Inimmune receives Small Business Innovation Research Contract to develop novel treatments targeting Allergic Rhinitis.

Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded $1,836,453 from the National Institute for Allergy and…
Read More
Inimmune Receives $598K Small Business Innovation Research Contract to Advance Vaccine Technologies

Inimmune Receives $598K Small Business Innovation Research Contract to Advance Vaccine Technologies

Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded Phase I Small Business Innovation Research (SBIR) award…
Read More
Inimmune - Montana Ambassadors Business of the Year

Inimmune - Montana Ambassadors Business of the Year

Missoula-based Inimmune Corporation was named the Montana Ambassadors Business of the Year in an announcement this week by Governor Gianforte.…
Read More
UM Taking Montana Technology Corridor to Next Level

UM Taking Montana Technology Corridor to Next Level

Looking to build on Missoula’s reputation as a community that fosters innovative thinkers, the University of Montana and its Montana…
Read More
Inimmune Welcomes New Chief Medical Officer

Inimmune Welcomes New Chief Medical Officer

January 7th, 2022 Missoula, MT Inimmune (Missoula, MT), a biotechnology company focused on devleoping the next generation of vaccines and…
Read More
Inimmune Named in Top 20 Innovative Immuno-Oncology Companies in the US

Inimmune Named in Top 20 Innovative Immuno-Oncology Companies in the US

The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It…
Read More

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics.

Facebook-f Twitter Linkedin

Quick Links

Contact

  • 1121 E Broadway St, Ste 106, Missoula, MT, 59802
  • 406-541-5913
  • info@inimmune.com

© Copyright 2022 Inimmune. All Rights Reserved.

Website Design by Digital Marketing Missoula
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go

TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING